A method for detecting mRNA regulatory activity in mammalian oocytes
By constructing a plasmid containing the CDS and introns of the SOX10 gene, activating the NMD pathway, and using GFP fluorescence detection, the problem of detecting the regulatory activity of mammalian oocyte mRNA was solved, enabling the assessment of oocyte quality and early embryonic developmental potential.
Patent Information
- Application Number
- CN202311447108.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-02
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-11-02
AI Technical Summary
Current technologies have failed to effectively detect mRNA regulatory activity in mammalian oocytes, especially NMD levels, which affects oocyte quality assessment and early embryonic developmental potential evaluation.
A plasmid containing the CDS and introns of the SOX10 gene was constructed. The NMD pathway was activated by prematurely stopping the codon. RNA clearance level was detected using GFP fluorescence. Combined with plasmid transfection into HeLa cells and microinjection into oocytes, mRNA regulatory activity was detected.
It can detect NMD levels and RNA degradation in oocytes, screen for embryonic arrest caused by incomplete degradation of maternal mRNA, assess early embryonic developmental potential, and provide markers for oocytes that do not cleave after fertilization.
Smart Images

Figure CN117512205B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of gene detection technology, specifically relating to a method for detecting the regulatory activity of mRNA in mammalian oocytes. Background Technology
[0002] Normal fertilization and reproduction in mammals are crucial for maintaining and perpetuating their populations. Egg quality is particularly important in this process.
[0003] Many factors influence the quality of oocytes in female mammals, primarily characterized by oocyte immaturity. Poor oocyte quality after fertilization can further impair embryonic development, leading to abnormal birth. Accurate assessment of oocyte quality is crucial for understanding the mechanisms of oocyte development and early embryonic development. The transition of gene expression patterns from oocyte to early embryo, known as the "maternal-zygotic transition," is the first critical event in early embryonic development. Timely degradation of maternal mRNA is an important prerequisite for the activation of embryonic genome transcription. Analysis of oocytes and arrested early embryos from some clinical patients has revealed significant accumulation of maternal mRNA, but the specific mechanisms remain unclear.
[0004] Nonsense-mediated mRNA decay (NMD) is an evolutionarily conserved RNA quality control mechanism present in all eukaryotes. It primarily degrades abnormal mRNAs containing premature stop codons, preventing the accumulation of harmful, truncated protein products that could damage cells. It also plays a role in maintaining normal mRNA homeostasis. However, there are currently no reports on detecting NMD levels in oocytes, nor are there any reports of abnormal NMD levels being associated with oocyte quality. Therefore, a method for detecting mRNA regulatory activity in mammalian oocytes is needed. Summary of the Invention
[0005] The purpose of this invention is to provide a method for detecting mRNA regulatory activity in mammalian oocytes, so as to solve the problems mentioned in the background art.
[0006] To achieve the above objectives, the present invention provides the following technical solution: a method for detecting mRNA regulatory activity in mammalian oocytes, comprising the following steps:
[0007] Step 1: Construct a CDS containing the SOX10 gene and a plasmid with intron 3 inserted into the CDS region, and then construct a plasmid that can generate an early stop codon.
[0008] Step 2: After transfecting the plasmid into HeLa cells, immunofluorescence staining was performed. The brightness of GFP was used to represent the expression of SOX10 and to further confirm the effect of the plasmid.
[0009] Step 3: After in vitro transcription of the plasmid and microinjection into GV-stage oocytes, immunofluorescence staining was performed. The brightness of GFP was used to represent the expression of SOX10, indicating the level of RNA clearance in the oocytes.
[0010] Preferably, the construction of the plasmid capable of activating NMD in step one includes inserting an intron between a segment of CDS, while simultaneously forming an early stop codon through point mutation 55 nt before the intron.
[0011] Preferably, the construction of the plasmid capable of activating NMD in step one includes forming a fusion protein with the target protein using GFP protein, and the expression of the target protein can be represented by the fluorescence level of GFP.
[0012] Preferably, in step two, when transfecting HeLa cells with a plasmid that can activate NMD, the plasmid also includes transfecting with a plasmid expressing mCherry, which can be used to eliminate problems in the operation process.
[0013] Preferably, in step three, when performing microinjection on GV stage oocytes, the level of RNA clearance in the oocytes is indicated by comparing the fluorescence levels of GFP in oocytes containing an early stop codon with those containing a normal CDS.
[0014] Preferably, the plasmid constructed in step one is a CDS containing the human SOX10 gene, a CDS containing introns, or a CDS containing introns that produces three early stop codons.
[0015] Preferably, the main steps include: collecting HeLa cells to be lysed and quickly placing them into a 1.5 mL centrifuge tube, adding 1 mL of Trizol (Invitrogen), and mixing thoroughly by pipetting to ensure complete cell lysis; this operation is best performed on ice to prevent mRNA degradation; adding 200 μL of chloroform to the lysis buffer and vigorously vortexing until the liquid turns milky white; incubating at room temperature for 5 minutes, then centrifuging at 12000g for 10 minutes in a refrigerated centrifuge at 4 degrees Celsius; after centrifugation, the liquid will separate into three phases: an upper aqueous phase, a middle protein phase, and a bottom chloroform phase; RNA is located in the upper aqueous phase; therefore, the upper phase is aspirated by pipetting. Transfer the colorless aqueous phase to a new 1.5 mL centrifuge tube containing 200 μL of chloroform. Vigorously vortex to mix thoroughly and allow to stand at room temperature for 2-3 minutes. Centrifuge at 12000 g for 15 minutes in a refrigerated centrifuge at 4°C. Transfer the upper colorless aqueous phase back to a new 1.5 mL centrifuge tube, add an equal volume of isopropanol, gently invert to mix, and allow to stand at room temperature for 10 minutes. Centrifuge at 12000 g for 15-30 minutes in a refrigerated centrifuge at 4°C. Carefully aspirate the excess liquid with a pipette and add 1 mL of chloroform. Resuspend the RNA in 75% ethanol by inverting the centrifuge tube. Centrifuge at 12000g for 5 minutes in a refrigerated centrifuge at 4°C, discard the ethanol, and centrifuge again at 12000g for 1 minute to remove all liquid adhering to the tube wall. Remove the liquid with a pipette, add 20μL of RNase-free water, and incubate at room temperature for 10 to 20 minutes until the white precipitate at the bottom of the tube becomes transparent. Measure the RNA concentration using Nanodrop.
[0016] Preferably, the main steps include: placing 1 μg of RNA in a PCR tube, adding 1 μL of Random 6mers and 1 μL of dNTP Mixture, adding RNase-free water to a final volume of 10 μL, and heating at 65°C for 5 minutes in an RCR instrument; removing the tube and placing it on ice, then adding 4 μL of 5×Prime Script II Buffer, 0.5 μL of RNase Inhibitor, and 1 μL of Prime Script II RTase to the PCR tube, adding RNase-free water to a final volume of 20 μL, and reacting in an RCR instrument; wherein the PCR reaction conditions are 30°C for 10 minutes, 42°C for 60 minutes, and 72°C for 15 minutes;
[0017] Subsequently, cDNA was used as a template for PCR. The PCR reaction system was prepared using the PCR SuperMix kit and PCR was performed to amplify the CDS of SOX10 and the DNA fragment with restriction enzyme sites added at both ends, so as to facilitate subsequent ligation with the existing backbone. The PCR reaction conditions were 95 degrees for 3 min, (95 degrees for 30 s, 60 degrees for 30 s, 72 degrees for 30 s), 72 degrees for 10 min, and 4 degrees. The PCR products were subjected to agarose gel electrophoresis, and then the target band was recovered under UV light using a gel recovery kit.
[0018] This DNA fragment was simultaneously double-digested with the PRK5-Flag-GFP plasmid backbone already available in our laboratory. The digestion products were ligated using a T4 ligase (Thermo) kit. The ligation products were then transformed, plated, single clones were picked, and cultured in LB medium before being sent for sequencing and sequence alignment.
[0019] Preferably, the main process includes: taking 100 μL of the bacterial culture from the previous step into 30 mL of LB medium containing 1‰ Ampmycin resistance, and culturing it at 37°C and 220 rpm for 16 hours on a shaker; centrifuging at 4000 x g for 10 min at room temperature to collect the bacterial cells; discarding the culture medium, adding 2.5 mL of Solution I / RNase A mixture to the precipitate, and vortexing to completely resuspend the cells; adding 2.5 mL of Solution II, and gently inverting to mix 8-10 times; adding 1.25 mL of pre-chilled N3 Buffer, and gently inverting to mix the centrifuge tube several times until a white flocculent precipitate forms, which can be incubated at room temperature for 2 min, followed by centrifugation at 15000 x g for 10 min at 4°C to remove precipitate impurities, and then collecting the supernatant into a collection tube; adding 0.1 volume of ETR. Solution: Invert and mix 10 times, then let stand in an ice bath for 10 minutes; incubate the lysis buffer in a 42°C water bath for 5 minutes; then centrifuge at 4000 x g for 5 minutes at room temperature. The ETR solution will form a blue layer at the bottom of the test tube; transfer the supernatant to another new 15 mL test tube, add 0.5 times the volume of anhydrous ethanol, gently invert the test tube 6-7 times, and let stand at room temperature for 1-2 minutes; Insert the DNA Midi binding column into a 15 mL collection tube, transfer 3.5 mL of the mixture obtained in the previous step into the binding column, centrifuge at 5000 x g for 3 min at room temperature, and discard the filtrate; insert the binding column into the collection tube, add 3 mL of HBC Buffer, centrifuge at 4000 x g for 3 min at room temperature, and discard the filtrate; insert the binding column into the collection tube, add 3.5 mL of DNA Wash Buffer (diluted with anhydrous ethanol), centrifuge at 4000 x g for 3 min at room temperature, and discard the filtrate; repeat this step; insert the binding column into the collection tube, centrifuge at 4000 x g for 10 min at room temperature to dry the binding column matrix; insert the binding column into a clean 15 mL centrifuge tube, add 0.5 mL of Endo-Free Elution Buffer to the binding column matrix, let stand at room temperature for 3 min, centrifuge at 4000 x g for 5 min to elute the DNA, and measure the concentration using Nanodrop;
[0020] Using PRK5-Flag-GFP-SOX10 plasmid as a template for PCR, the PCR reaction system was prepared using the PCR SuperMix kit (Vazyme), and PCR was performed to amplify the linearized plasmid. The PCR reaction conditions were: 95°C for 5 min, (95°C for 30 s, 60°C for 30 s, 72°C for 30 s), 72°C for 10 min, and 4°C; steps 2 to 4 were repeated 35 times. Simultaneously, HeLa cell DNA was used as a template for PCR. The PCR reaction system was prepared using the SuperMix kit (Vazyme) and PCR was performed to amplify intron 3 of SOX10. The PCR reaction conditions were 95°C for 3 min, (95°C for 30 s, 60°C for 30 s, 72°C for 30 s), 72°C for 10 min, and 4°C. The amplified products were subjected to agarose gel electrophoresis and the target DNA fragment was recovered. Using the seamless cloning kit (Vazyme), intron 3 was inserted between exon 3 and exon 4 of the CDS region of SOX10 in the PRK5-Flag-GFP-SOX10 plasmid. The ligation product was transformed with DH5α and plated. Single clones were picked, expanded in LB medium, and sent for sequencing. After sequence alignment, the plasmid was extracted using the kit (AXYGEN) to obtain the PRK5-Flag-GFP-SOX10-intron plasmid.
[0021] Preferably, the main steps include: in a 12-well plate, when HeLa cells reach a density of 70%-80%, discard the original culture medium and add 1 mL of serum-free culture medium to each well; dilute 1.5 μg of LIPOFECTAMINE 2000 reagent in 50 μL of Opti-MEM medium in each well, and simultaneously dilute 0.5 μg of NMD reporter plasmid and 0.5 μg of HA-mCherry plasmid in 50 μL of Opti-MEM medium as controls, and incubate at room temperature for 5 minutes; mix the diluted plasmid DNA and diluted LIPOFECTAMINE 2000, and let stand at room temperature for 20 minutes; then evenly add the above mixture to the cells; after culturing at 37°C, 5% CO2, and 100% saturated humidity for 5 hours, replace each well with 1 mL of fresh DMEM culture medium containing 10% FBS, and continue culturing; collect samples 24 hours after transfection for immunofluorescence staining;
[0022] The main steps include: removing the cell culture plate, discarding the culture medium, washing each well with 1 mL of PBS, adding 1 mL of 4% PFA, fixing for 30 minutes, and discarding the fixative; washing with 1 mL of PBS, adding 1 mL of 0.5% Triton X-100, permeabilizing for 30 minutes, and discarding the permeabilization solution; washing with 1 mL of PBS, adding 500 μL of DAPI staining solution, incubating at room temperature for 15 minutes, and discarding the staining solution; washing with 1 mL of PBS, adding 200 μL of antiquenching agent, and taking pictures under a confocal microscope.
[0023] Compared with the prior art, the beneficial effects of the present invention are:
[0024] 1. This invention can detect the level of NMD and the degree of RNA degradation in oocytes, and involves a method for screening embryonic arrest after fertilization due to incomplete degradation of maternal mRNA. Later, the developmental potential of early embryos can be judged by detecting whether target genes are normally degraded. When the embryo carries these genes and expresses them abnormally, it may lead to embryonic developmental arrest.
[0025] 2. This invention provides information on whether the abnormal expression of these target genes in early embryos can be used as a marker to determine whether an egg will not cleave after fertilization, plasmid construction for detecting NMD levels in eggs, cell transfection, in vitro transcription of plasmids, and microinjection of oocytes. Attached Figure Description
[0026] Figure 1 This is a schematic diagram illustrating the construction of the NMD reporter plasmid according to the present invention;
[0027] Figure 2 This is an immunofluorescence staining analysis diagram of HeLa cells after transfection with the NMD reporter plasmid of this invention;
[0028] Figure 3 This is an immunofluorescence staining analysis diagram of the NMD reporter plasmid of the present invention after in vitro transcription and injection into mouse oocytes. Detailed Implementation
[0029] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0030] Please see Figures 1 to 3 This invention provides a technical solution: a method for detecting mRNA regulatory activity in mammalian oocytes, comprising the following steps:
[0031] Step 1: Construct a plasmid containing the SOX10 gene CDS and inserting intron 3 into the CDS region. Then, construct a plasmid that can generate an early stop codon. Insert an intron between a segment of the CDS and generate an early stop codon by point mutation 55 nt before the intron. Use GFP protein to form a fusion protein with the target protein. The expression of the target protein can be represented by the fluorescence level of GFP.
[0032] Step 2: After transfecting the plasmid into HeLa cells, immunofluorescence staining is performed. The brightness of GFP represents the expression of SOX10 and further confirms the effect of this plasmid. In addition to this plasmid, a plasmid expressing mCherry is also transfected to eliminate problems in the operation process.
[0033] Step 3: After in vitro transcription of the plasmid and microinjection into GV-stage oocytes, immunofluorescence staining was performed. The brightness of GFP was used to represent SOX10 expression to show the level of RNA clearance in oocytes. The level of RNA clearance in oocytes was shown by comparing the fluorescence levels of GFP injected into oocytes containing an early stop codon with those containing a normal CDS.
[0034] By constructing a plasmid containing the SOX10 gene CDS and inserting intron 3 into the CDS region, and further generating premature stop codons by point mutations at different CDS positions on the intron-containing plasmid, HeLa cells were transfected and immunofluorescence staining was performed 24 hours later. The expression of SOX10 was indicated by the expression of GFP on the plasmid. The GFP brightness of the plasmid containing the premature stop codon was significantly weaker than that of the plasmid containing the CDS or the intron, indicating that the plasmid containing the premature stop codon activated the NMD pathway and initiated RNA degradation. Four-week-old female mice were injected with PMSG and GV stage oocytes were harvested. The plasmid was transcribed in vitro and then microinjected into the oocytes. After culturing in M16 medium containing milrinone for 24 hours, immunofluorescence staining was performed. The results showed that the GFP brightness of the oocytes injected with the plasmid containing the premature stop codon was weaker than that of the oocytes injected with the plasmid containing the CDS or the intron, indicating that the NMD pathway was successfully activated and RNA degradation was initiated. This demonstrates that this method can detect the level of NMD and the degree of RNA degradation in oocytes.
[0035] As can be seen from the above description, the present invention has the following beneficial effects: The present invention can detect the level of NMD and the degree of RNA degradation in oocytes, and involves a method for screening embryonic arrest after fertilization due to incomplete degradation of maternal mRNA. In the later stage, the developmental potential of early embryos can be judged by detecting whether the target genes are normally degraded. When the embryo carries these genes and expresses them abnormally, it may lead to embryonic developmental arrest.
[0036] For further details, please refer to Figure 1 , Figure 1 The diagrams show five plasmids, the latter three of which contain early stop codons.
[0037] In one specific embodiment, the main steps include:
[0038] Collect HeLa cells to be lysed and quickly transfer them to a 1.5 mL centrifuge tube. Add 1 mL of Trizol (Invitrogen) and mix thoroughly by pipetting to ensure complete cell lysis. This process is best performed on ice to prevent mRNA degradation. Add 200 μL of chloroform to the lysis buffer and vortex vigorously until the liquid turns milky white. Incubate at room temperature for 5 minutes, then centrifuge at 12000 g for 10 minutes in a refrigerated centrifuge at 4°C. After centrifugation, the liquid will separate into three phases: an aqueous phase on top, a protein phase in the middle, and a chloroform phase at the bottom. RNA is located in the upper aqueous phase. Therefore, pipette the colorless upper aqueous phase into a new 1.5 mL centrifuge tube containing 200 μL of chloroform, vortex vigorously to mix thoroughly, and incubate at room temperature for 2-3 minutes; then centrifuge at 12000 g for 15 minutes in a refrigerated centrifuge at 4°C. Transfer the colorless aqueous supernatant to a new 1.5 mL centrifuge tube using a pipette tip. Add an equal volume of isopropanol, gently invert to mix, and incubate at room temperature for 10 minutes. Centrifuge at 12000g for 15 to 30 minutes in a refrigerated centrifuge at 4°C. Carefully aspirate the excess liquid with a pipette tip, add 1 mL of 75% ethanol, and invert the centrifuge tube to resuspend the RNA. Centrifuge at 12000g for 5 minutes in a refrigerated centrifuge at 4°C, discard the ethanol, and centrifuge again at 12000g for 1 minute. Centrifuge to remove all liquid adhering to the tube wall, remove the excess liquid with a pipette, add 20 μL of RNase-free water, and incubate at room temperature for 10 to 20 minutes, until the white precipitate at the bottom of the tube becomes clear. Measure the RNA concentration using a Nanodrop.
[0039] cDNA was obtained using a reverse transcription kit (Takara).
[0040] In one specific embodiment, the main steps include: placing 1 μg of RNA in a PCR tube, adding 1 μL of Random 6mers and 1 μL of dNTP Mixture, and then adding RNase-free water to a final volume of 10 μL. The tube is then heated at 65°C for 5 minutes in an RCR instrument. The tube is removed and placed on ice. In the PCR tube, 4 μL of 5×Prime Script II Buffer, 0.5 μL of RNase Inhibitor, and 1 μL of Prime Script II RTase are added, and RNase-free water is added to a final volume of 20 μL. The PCR reaction is then carried out in an RCR instrument. The PCR reaction conditions are: 30°C for 10 minutes, 42°C for 60 minutes, and 72°C for 15 minutes.
[0041] Subsequently, using cDNA as a template for PCR, the PCR reaction system was prepared using the PCR SuperMix kit and PCR was performed to amplify the SOX10 CDS and the DNA fragment with restriction enzyme sites added at both ends, for subsequent ligation with the existing backbone. The PCR reaction conditions were: 95°C for 3 min, (95°C for 30 s, 60°C for 30 s, 72°C for 30 s), 72°C for 10 min, and 4°C. Steps 2 to 4 were repeated 35 times.
[0042] The F primer sequence is: CCGCTCGAGATGGCGGAGGAGC
[0043] The R primer sequence is: CCCAAGCTTTTAGGGCCGGGACAGTG
[0044] The PCR products were subjected to agarose gel electrophoresis, and the target band was then recovered under UV light using a gel recovery kit.
[0045] In one specific embodiment, the gel recovery process includes: cutting the gel containing the target fragment and transferring it to a 1.5 ml centrifuge tube (the centrifuge tube has already been weighed), weighing the gel block to obtain its weight, and converting it to an approximate volume using the formula 100 mg = 100 μL. Add 3 volumes of Buffer DE-A and incubate in a 65°C water bath for approximately 7 minutes until the gel is completely melted, shaking every 2-3 minutes. Add half the volume of Buffer DE-A of Buffer DE-B and mix thoroughly. Place a DNA preparation tube into a 2 ml collection tube and transfer the entire molten gel solution into the preparation tube. Centrifuge at 12,000 x g for 1 minute at room temperature. Discard the filtrate in the collection tube and reattach the preparation tube to the 2 ml collection tube. Add 500 μL of Buffer W1 to the preparation tube and centrifuge at 12,000 x g for 1 minute. Discard the filtrate in the collection tube and reattach the column to the 2 ml collection tube. Add 700 μL of Buffer W2 to the preparation tube. Centrifuge at 12,000 x g for 1 min at room temperature. Discard the filtrate in the collection tube, and reattach the column to the 2 ml collection tube. Repeat this step once. Discard the filtrate in the collection tube, and reattach the preparation tube to the 2 ml collection tube. Centrifuge at 13,000 x g for 2 min to remove residual liquid. Attach the preparation tube to a 1.5 ml centrifuge tube, add 20 μL of water, incubate at room temperature for 1 min, and centrifuge at 13,000 x g for 1 min to elute DNA. Measure the concentration using Nanodrop.
[0046] This DNA fragment was simultaneously double-digested with the PRK5-Flag-GFP plasmid backbone already available in our laboratory to produce the same sticky ends.
[0047] In one specific embodiment, the double enzyme digestion process includes: placing 1 μg of DNA fragment and PRK5-Flag-GFP plasmid into two PCR tubes, respectively; then adding 1 μL of EcoRI, 1 μL of HindIII, and 5 μL of 10×M Buffer to each tube, and adding water to a final volume of 50 μL. After mixing, the mixture is incubated at 37°C for 2 hours in a PCR instrument. Subsequently, the target DNA fragment is subjected to agarose gel electrophoresis as described above, and the gel is recovered, with the concentration measured using Nanodrop.
[0048] The T4 ligase (Thermo) kit was used to ligate the enzyme digestion products. The specific procedure is as follows: 50 ng of the double-digested DNA fragment and 150 ng of plasmid were placed in a PCR tube, followed by the addition of 1 μL of T4 DNA Ligase, 2 μL of T4 DNA Ligase Buffer, and water to a final volume of 20 μL. After mixing, the mixture was incubated at 37°C for 30 minutes in a PCR instrument, followed by pre-cooling on ice for 5 minutes.
[0049] The ligation product was transformed, plated, and single colonies were picked. After expansion culture in LB medium, the culture was sent for sequencing. The specific procedure is as follows: Competent cells (100 μL / tube) were removed at -80℃, and at least 10 μL of reaction solution was added. The tube was gently tapped several times to mix, and the mixture was placed on ice for 30 min, then incubated in a 42℃ water bath for 45 s, and then on ice for 2 min. 900 μL of LB medium was added to the EP tube, and the mixture was incubated at 37℃ with a shaker at 220 rpm for 1 hour. Then, the tube was centrifuged at 5000 rpm for 3 minutes. 900 μL of supernatant was aspirated, leaving 100 μL. The precipitate was resuspended. The mixture was evenly spread onto a plate containing an appropriate amount of Ampmycin. The plate was inverted and incubated overnight at 37℃ (12 hours). A single colony was picked and placed in 3 mL of LB medium containing 1‰ Ampmycin resistance. After incubation at 37℃ with a shaker at 220 rpm for 10 hours, 1 mL was sent to the sequencing company.
[0050] After sequence alignment, the plasmid can be extracted using a kit to obtain the PRK5-Flag-GFP-SOX10 plasmid.
[0051] In one specific embodiment, the process includes: taking 100 μL of the bacterial culture from the previous step into 30 mL of LB medium containing 1‰ Ampmycin resistance, and culturing it at 37°C and 220 rpm for 16 hours on a shaker. Centrifuging at 4000 xg for 10 min at room temperature to collect the bacterial cells. Discarding the culture medium, adding 2.5 mL of Solution I / RNase A mixture to the precipitate, and vortexing to completely resuspend the cells. Adding 2.5 mL of Solution II, and gently inverting to mix 8-10 times. Adding 1.25 mL of pre-chilled N3 Buffer, and gently inverting to mix the centrifuge tube several times until a white flocculent precipitate forms. Incubating at room temperature for 2 min, followed by centrifugation at 15000 xg for 10 min at 4°C to remove precipitate impurities, and then collecting the supernatant in a collection tube. Adding 0.1 volume of ETRSolution, inverting to mix 10 times, and then incubating on ice for 10 min. Incubating the above lysis buffer in a water bath at 42°C for 5 min. Next, centrifuge at 4000xg for 5 minutes at room temperature. The ETR solution will form a blue layer at the bottom of the test tube. Transfer the supernatant to a new 15mL test tube, add 0.5 times the volume of anhydrous ethanol, gently invert the test tube 6-7 times, and let it stand at room temperature for 1-2 minutes. Insert the DNAMidi binding column into a 15 mL collection tube, transfer 3.5 mL of the mixture obtained in the previous step to the binding column, centrifuge at 5000 x g for 3 min at room temperature, and discard the filtrate. Insert the binding column into the collection tube, add 3 mL of HBC Buffer, centrifuge at 4000 x g for 3 min at room temperature, and discard the filtrate. Insert the binding column into the collection tube, add 3.5 mL of DNA Wash Buffer (diluted with anhydrous ethanol), centrifuge at 4000 x g for 3 min at room temperature, and discard the filtrate. Repeat this step. Insert the binding column into the collection tube, centrifuge at 4000 x g for 10 min at room temperature to dry the binding column matrix. Insert the binding column into a clean 15 mL centrifuge tube, add 0.5 mL of Endo-Free Elution Buffer to the binding column matrix, incubate at room temperature for 3 min, centrifuge at 4000 x g for 5 min to elute the DNA, and measure the concentration using Nanodrop.
[0052] Using the PRK5-Flag-GFP-SOX10 plasmid as a template for PCR, the PCR reaction system was prepared using the PCR SuperMix kit, and PCR was performed to amplify the linearized plasmid. The PCR reaction conditions were: 95°C for 5 min, (95°C for 30 s, 60°C for 30 s, 72°C for 30 s), 72°C for 10 min, and 4°C. Steps 2 to 4 were repeated 35 times.
[0053] The F primer sequence is: GCTGCTGAACGAAAGTGACAAG
[0054] The R primer sequence is: CCACTCCTCTGTGACACTTTAGCCCTCCGA
[0055] Simultaneously, using HeLa cell DNA as a template for PCR, the PCR reaction system was prepared using the PCR SuperMix kit and PCR was performed to amplify intron 3 of SOX10. The PCR reaction conditions were: 95°C for 3 min, (95°C for 30 s, 60°C for 30 s, 72°C for 30 s), 72°C for 10 min, and 4°C. Steps 2 to 4 were repeated 35 times.
[0056] The F primer sequence is: GCTCTGTCATCAGCACTCACGCCAGAGCCATGGCCCAC
[0057] The R primer sequence is: GTGAGTGCTGATGACAGAGCTGA
[0058] The amplification products were subjected to agarose gel electrophoresis, and the target DNA fragment was recovered. Using a seamless cloning kit, intron 3 was inserted between exon 3 and exon 4 of the CDS region of SOX10 in the PRK5-Flag-GFP-SOX10 plasmid. The ligation product was transformed with DH5α and plated. Single clones were selected, expanded in LB medium, and then sent for sequencing. After sequence alignment, the plasmid was extracted using a kit to obtain the PRK5-Flag-GFP-SOX10-intron plasmid.
[0059] In one specific embodiment, the seamless cloning process includes: placing 160 ng of intron DNA fragment and 120 ng of plasmid fragment into PCR tubes, respectively; then adding 2 μL of Exnase, 4 μL of 5×CEⅡ Buffer, and water to a final volume of 20 μL. After mixing, incubate at 37°C for 30 minutes in a PCR instrument, then pre-cool on ice for 5 minutes. Gently mix and briefly centrifuge, then incubate at 37°C for 30 minutes in a PCR instrument, followed immediately by cooling on ice.
[0060] Subsequently, using the PRK5-Flag-GFP-SOX10-intron plasmid as a template for PCR, the PCR reaction system was prepared using the PCR SuperMix kit and PCR was performed to amplify the product containing the specific base mutation. The PCR reaction conditions were: 94°C for 5 min, (94°C for 30 s, 64°C for 30 s, 72°C for 30 s), 72°C for 10 min, and 4°C. Steps 2 to 4 were repeated 35 times.
[0061] The F primer sequence for Y83X is: GCCAGGTGCTCAGCGGCTAAGACTGGACGCTGGTGCC
[0062] The R primer sequence for Y83X is GGGCACCAGCGTCCAGTCTTAGCCGCTGAGCACCTG
[0063] The F primer sequence for E189X is: GCCCAGGGCGAGGCGTAGTGCCCCGGTGGGGAG
[0064] The R primer sequence for E189X is: CCTCCCCACCGGGGCACTACGCCTCGCCCTGGG
[0065] The F primer sequence for Y207X is: GCCATCCAGGCCCACTAAAAGAGCGCCCACTTGGACCAC. The R primer sequence for Y207X is: GGTCCAAGTGGGCGCTCTTTTAGTGGGCCTGGATG.
[0066] After PCR amplification, 1 μL of DpnI enzyme was added for digestion, and the mixture was placed in a 37°C incubator for 2 hours to thoroughly digest the original DNA plasmid template. The PCR product was transformed with DH5α and plated. Single clones were picked, amplified in LB medium, and then sent for sequencing. After sequence alignment, plasmids were extracted using a kit to obtain PRK5-Flag-GFP-SOX10-Y83X, PRK5-Flag-GFP-SOX10-E189X, and PRK5-Flag-GFP-SOX10-Y207X plasmids.
[0067] These five plasmids were transfected into HeLa cells, and samples were collected 24 hours later for immunofluorescence staining.
[0068] Please see Figure 2 , Figure 2 The results showed that the SOX10 gene was normally expressed after being transformed into HeLa cells using the plasmids PRK5-Flag-GFP-SOX10 and PRK5-Flag-GFP-SOX10-intron. However, when plasmids containing premature stop codons, PRK5-Flag-GFP-SOX10-Y83X, PRK5-Flag-GFP-SOX10-E189X, and PRK5-Flag-GFP-SOX10-Y207X, were transformed into HeLa cells, its expression was significantly weakened.
[0069] In one specific embodiment, the main steps include:
[0070] In 12-well plates, when HeLa cells reach a confluence density of 70%–80%, discard the original culture medium and add 1 mL of serum-free culture medium to each well. Dilute 1.5 μL of LIPOFECTAMINE 2000 reagent in 50 μL of Opti-MEM medium to each well, and use 0.5 μg of NMD reporter plasmid and 0.5 μg of HA-mCherry plasmid diluted in 50 μL of Opti-MEM medium as controls. Incubate at room temperature for 5 minutes. Mix the diluted plasmid DNA and diluted LIPOFECTAMINE 2000 and incubate at room temperature for 20 minutes. Then, add the mixture evenly to the cells. Incubate at 37°C, 5% CO2, and 100% saturated humidity for 5 hours, then replace each well with 1 mL of fresh DMEM medium containing 10% FBS and continue culturing. After 24 hours, replace the original culture medium with fresh DMEM medium containing 10% FBS and continue culturing. Collect samples 24 hours after transfection for immunofluorescence staining.
[0071] In one specific embodiment, the main steps include: removing the cell culture plate, discarding the culture medium, washing each well with 1 mL of PBS, adding 1 mL of 4% PFA, fixing for 30 minutes, and discarding the fixative. Washing once with 1 mL of PBS, adding 1 mL of 0.5% Triton X-100, permeabilizing for 30 minutes, and discarding the permeabilization solution. Washing once with 1 mL of PBS, adding 500 μL of DAPI staining solution, incubating at room temperature for 15 minutes, and discarding the staining solution. Washing once with 1 mL of PBS, adding 200 μL of anti-quenching agent, and taking pictures under a confocal microscope.
[0072] These five plasmids were transcribed in vitro and then injected into GV phase oocytes. After culturing for 24 hours, samples were collected for immunofluorescence staining.
[0073] Please see Figure 3 , Figure 3 The results showed that the SOX10 gene was normally expressed after injection of the two plasmids PRK5-Flag-GFP-SOX10 and PRK5-Flag-GFP-SOX10-intron. However, its expression was attenuated after injection of plasmids containing early stop codons, namely PRK5-Flag-GFP-SOX10-Y83X, PRK5-Flag-GFP-SOX10-E189X, and PRK5-Flag-GFP-SOX10-Y207X.
[0074] In one specific embodiment, the main steps include:
[0075] Obtaining GV stage oocytes:
[0076] Four-week-old female mice were selected and injected with 5 units of PMSG to simulate in vivo FSH to promote follicle development. After 44-48 hours of PMSG treatment, the mice were euthanized by cervical dissection, and the ovaries were removed and placed in M2 culture medium. To prevent spontaneous glutamate-void dysplasia (GVBD) in vitro, milrinone was added to the culture medium at a final concentration of 1 μM to inhibit GVBD. Then, in M2 culture medium, large follicles in the ovaries were punctured with a 1 mL syringe needle to release cumulus-oocyte complexes (COCs). The COCs were collected and repeatedly pipetted using a pipette 1.5 times the diameter of the oocyte until the cumulus cells surrounding the oocyte were removed. The collected oocytes were washed with clean M2 culture medium and then placed in M16 culture drops containing milrinone for further culture. The ratio of oocytes to M16 culture medium was approximately 1 oocyte per 2 μL of culture medium, and mineral oil was added to form a liquid seal to maintain long-term stability of the culture medium. Oocytes were cultured at a constant temperature of 37 degrees Celsius in a 5% high-purity CO2 incubator.
[0077] Plasmid linearization: Take 10 μg of plasmid in a PCR tube, add 5 μL of HindIII restriction enzyme, add 15 μL of buffer, and finally add water to make up to 150 μL. After placing in a 37°C oven for 4 hours, purify the DNA using an Axygen PCR cleaning kit, and finally elute with 20 μL of nuclease-free water into a nuclease-free centrifuge tube.
[0078] In vitro transcription was performed using the SP6 (AM 1340) kit. 1 μg of linearized plasmid was placed in a 1.5 mL centrifuge tube, along with 10 μL of 2X NTP / CAP, 2 μL of 10X Reaction Buffer, and 2 μL of Enzyme Mix. Water was added to bring the volume to 20 μL. The mixture was thoroughly mixed by pipetting and incubated at 37°C for 4 hours. 1 μL of TURBO DNase was then added, and the mixture was returned to the 37°C incubator for another 15 minutes to digest the DNA template.
[0079] To improve translation efficiency, an AM1350 kit was used for in vitro poly(A) tailing. In the centrifuge tube from the previous step, 36 μL of Nuclease-free Water, 20 μL of 5X E-PAP Buffer, 10 μL of 25 mM MnCl2, 10 μL of 10 mM ATP, and 4 μL of E-PAP were added. The mixture was thoroughly mixed by pipetting and incubated at 37°C for 1 hour. Then, 50 μL of LiCl was added, and the tube was placed in a -20°C freezer for 1 hour to precipitate RNA. The sample was then centrifuged at maximum speed for 15 minutes in a 4°C refrigerated centrifuge. After centrifugation, a white RNA precipitate was observed at the bottom of the tube. The supernatant was discarded, and 1 mL of 70% ethanol was added. The tube was inverted to resuspend the RNA. The sample was centrifuged again at maximum speed for 15 minutes in a 4°C refrigerated centrifuge. The ethanol was discarded, and the tube was centrifuged again at 12000g for 1 minute to remove any liquid adhering to the tube walls. All liquid was then removed using a pipette. Place at room temperature for 10 to 20 minutes, until the white precipitate at the bottom of the tube becomes transparent. Add 20 μL of water to dissolve the RNA and then store in a -80°C freezer.
[0080] Microinjection was performed using a microinjection apparatus. GV-stage oocytes were placed into 10 μL micromanipulation drops prepared with M2 culture medium and sealed with mineral oil to maintain a constant osmotic pressure within the droplets. Milrinone was added to the culture medium at a final concentration of 1 μM to inhibit GVBD. Approximately 7 μL of oocytes were injected per injection cell. After injection, oocytes with good condition and viability were selected and transferred to M16 medium containing 1 μM milrinone, and cultured at 37°C in a 5% CO2 incubator for 24 hours before being photographed under a fluorescence microscope.
[0081] It should be noted that, in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Without further limitations, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.
[0082] The above description is only used to illustrate the technical solution of the present invention and is not intended to limit it. Any other modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention, as long as they do not depart from the spirit and scope of the technical solution of the present invention, should be covered within the scope of the claims of the present invention.
Claims
1. A method for detecting mRNA regulatory activity in GV stage oocytes of mammalian mice, characterized in that, Includes the following steps: Step 1: Plasmid Construction: Construct a PRK5-Flag-GFP backbone plasmid containing the human SOX10 gene CDS. Insert an endogenous SOX10 intron 3 between exon 3 and exon 4 of the SOX10 gene CDS. Then, through point mutation, construct an early stop codon (PTC) 55 nt upstream of the intron 3 to obtain a reporter plasmid carrying the early stop codon. The reporter plasmid is a fusion protein of FLAG-EGFP and SOX10, and SOX10 protein expression is characterized by GFP fluorescence levels. The reporter plasmids carrying the early stop codon include Y83X, E189X, and Y207X mutant plasmids. Step 2: Pre-validation of reporter plasmid in somatic cells: The reporter plasmid obtained in Step 1 was co-transfected with the HA-mCherry control plasmid into HeLa cells. Immunofluorescence staining was performed 24 h after transfection. mCherry fluorescence was used to eliminate experimental errors caused by transfection operation. SOX10 expression was characterized by GFP fluorescence intensity to verify the effect of reporter plasmid in activating NMD. Step 3: Oocyte Microinjection and Detection: The validated reporter plasmid was transcribed in vitro to obtain in vitro transcribed RNA; the transcribed RNA was microinjected into mouse GV-stage oocytes that had been supplemented with milrinone to inhibit spontaneous GVBD; after 24 h of culture, immunofluorescence staining was performed; the GFP fluorescence levels of oocytes injected with reporter RNA carrying an early stop codon were compared with those injected with normal SOX10-CDS reporter RNA without PTC; the difference in GFP fluorescence intensity was used to characterize the level of NMD-mediated RNA clearance in oocytes; The site-directed mutagenesis primers used in step one to construct the reporter plasmid carrying the early stop codon are as follows: Y83X mutant plasmid: forward primer sequence is shown in SEQ ID NO:7, and reverse primer sequence is shown in SEQ ID NO:8; E189X mutant plasmid: forward primer sequence is shown in SEQ ID NO:9, and reverse primer sequence is shown in SEQ ID NO:10; Y207X mutant plasmid: forward primer sequence is shown in SEQ ID NO:11, and reverse primer sequence is shown in SEQ ID NO:
12.
2. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that: The construction of the plasmid capable of activating NMD in step one involves inserting an intron between a segment of CDS, and simultaneously forming an early stop codon through point mutation 55 nt before the intron.
3. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that: The construction of a plasmid capable of activating NMD in step one involves forming a fusion protein with the target protein using GFP protein, and using the fluorescence level of GFP to indicate the expression of the target protein.
4. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that: In step two, when transfecting HeLa cells with plasmids that can activate NMD, plasmids expressing mCherry are also transfected simultaneously to eliminate problems during the operation.
5. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that: In step three, when microinjecting GV stage oocytes, the level of RNA clearance in the oocytes is indicated by comparing the fluorescence levels of GFP in oocytes containing an early stop codon with those containing a normal CDS.
6. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that: The plasmids constructed in step one are CDS containing the human SOX10 gene, CDS containing introns, and CDS containing introns that generate three early stop codons.
7. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that, The steps include: Collect HeLa cells to be lysed and quickly transfer them to a 1.5 mL centrifuge tube. Add 1 mL of Trizol and mix thoroughly by pipetting to ensure complete cell lysis. Perform these procedures on ice to prevent mRNA degradation. Add 200 μL of chloroform to the lysis buffer and vortex vigorously until the liquid turns milky white. Let stand at room temperature for 5 minutes, then centrifuge at 12000 g for 10 minutes in a refrigerated centrifuge at 4°C. After centrifugation, the liquid will separate into three phases: an upper aqueous phase, a middle protein phase, and a bottom chloroform phase. RNA is located in the upper aqueous phase. Therefore, pipette the colorless upper aqueous phase into a... A new 1.5 mL centrifuge tube containing 200 μL of chloroform was added. The tube was vigorously vortexed to mix thoroughly and allowed to stand at room temperature for 2-3 minutes. The tube was then centrifuged at 12000g for 15 minutes in a refrigerated centrifuge at 4°C. The upper colorless aqueous phase was then transferred to a new 1.5 mL centrifuge tube, and an equal volume of isopropanol was added. The tube was gently inverted to mix and allowed to stand at room temperature for 10 minutes. The tube was then centrifuged at 12000g for 15-30 minutes in a refrigerated centrifuge at 4°C. The excess liquid was carefully aspirated with a pipette, and 1 mL of 75% ethanol was added. The tube was then inverted to resuspend the RNA. The tube was centrifuged at 12000g for 5 minutes in a refrigerated centrifuge at 4°C. The ethanol was discarded, and the tube was returned to the centrifuge and centrifuged at 12000g for 1 minute. All liquid adhering to the tube wall was centrifuged to the bottom of the tube and aspirated with a pipette. 20 μL of RNase-free water was added, and the tube was incubated at room temperature for 10-20 minutes until the white precipitate at the bottom of the tube became clear. The RNA concentration was then measured using a Nanodrop.
8. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that, step include: Place 1 μg of RNA in a PCR tube, add 1 μL of Random 6 mers and 1 μL of dNTP™ extract, and add RNase-free water to a final volume of 10 μL. Heat the tube at 65°C for 5 minutes in an RCR system. Remove the tube and place it on ice. Add 4 μL of 5×Prime Script II Buffer, 0.5 μL of RNase Inhibitor, and 1 μL of Prime Script II RTase to the PCR tube. Add RNase-free water to a final volume of 20 μL and react in an RCR system. The PCR reaction conditions are: 30°C for 10 minutes, 42°C for 60 minutes, and 72°C for 15 minutes. Subsequently, cDNA was used as a template for PCR. The PCR reaction system was prepared using the PCR SuperMix kit and PCR was performed to amplify the SOX10 CDS and the DNA fragment with restriction enzyme sites added at both ends, so as to facilitate subsequent ligation with the existing backbone. The PCR reaction conditions were 95°C for 3 min, 95°C for 30 s, 60°C for 30 s, 72°C for 30 s, 72°C for 10 min, and 4°C. The PCR products were subjected to agarose gel electrophoresis, and the target band was then recovered under UV light using a gel recovery kit. This DNA fragment was simultaneously double-digested with the PRK5-Flag-GFP plasmid backbone already available in our laboratory. The digestion products were ligated using a T4 ligase kit, the ligation products were transformed, plated, single clones were picked, and the samples were expanded in LB medium before being sent for sequencing and sequence alignment.
9. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that, The procedure includes: taking 100 μL of the bacterial culture from the previous step and adding it to 30 mL of LB medium containing 1‰ Ampmycin resistance, and incubating at 37°C and 220 rpm for 16 hours on a shaker; centrifuging at 4000 xg for 10 min at room temperature to collect the bacterial cells; discarding the culture medium, adding 2.5 mL of Solution I / RNase A mixture to the precipitate, and vortexing to completely resuspend the cells; adding 2.5 mL of Solution II, and gently inverting to mix 8-10 times; adding 1.25 mL of pre-chilled N3 Buffer, and gently inverting to mix the centrifuge tube several times until a white flocculent precipitate forms, incubating at room temperature for 2 min, then centrifuging at 15000 xg for 10 min at 4°C to remove precipitate impurities, and then aspirating the supernatant into a collection tube; adding 0.1 volume of ETRSolution, and inverting to mix 10 times. Then, incubate on ice for 10 minutes; incubate the lysis buffer in a 42°C water bath for 5 minutes; then centrifuge at 4000xg for 5 minutes at room temperature. The ETR solution will form a blue layer at the bottom of the test tube; transfer the supernatant to another new 15mL test tube, add 0.5 times the volume of anhydrous ethanol, gently invert the test tube 6-7 times, and incubate at room temperature for 1-2 minutes; insert the HiBind® DNA Midi binding column into a 15mL collection tube, transfer the 3.5mL mixture obtained in the previous step to the binding column, centrifuge at 5000xg for 3 minutes at room temperature, and discard the filtrate; insert the binding column into the collection tube, add 3 mL of HBC Buffer, centrifuge at 4000xg for 3 minutes at room temperature, and discard the filtrate; insert the binding column into the collection tube, add 3.5 mL of DNA Wash Buffer diluted with anhydrous ethanol, centrifuge at 4000xg for 3 minutes at room temperature, and discard the filtrate; repeat this step; insert the binding column into the collection tube, centrifuge at 4000xg for 3 minutes at room temperature. Centrifuge for 10 min to dry the binding column matrix; insert the binding column into a clean 15 mL centrifuge tube, add 0.5 mL of Endo-Free Elution Buffer to the binding column matrix, incubate at room temperature for 3 min, centrifuge at 4,000 x g for 5 min to elute the DNA, and measure the concentration using Nanodrop; Using PRK5-Flag-GFP-SOX10 plasmid as a template for PCR, the PCR reaction system was prepared using the PCR SuperMix kit and PCR was performed to amplify the linearized plasmid. The PCR reaction conditions were as follows: Step 1: 95°C for 5 min; Steps 2-4: 95°C for 30 s, 60°C for 30 s, 72°C for 30 s; Step 5: 72°C for 10 min, 4°C; Steps 2-4 were repeated 35 times. Simultaneously, HeLa cell DNA was used as a template for PCR. The SuperMix kit was used to prepare the PCR reaction system and perform PCR to amplify intron 3 of SOX10. The PCR reaction conditions were 95°C for 3 min, 95°C for 30 s, 60°C for 30 s, 72°C for 30 s, 72°C for 10 min, and 4°C. The amplified products were subjected to agarose gel electrophoresis and the target DNA fragment was recovered. Using a seamless cloning kit, intron 3 was inserted between exon 3 and exon 4 of the CDS region of SOX10 in the PRK5-Flag-GFP-SOX10 plasmid. The ligation product was transformed with DH5α and plated. Single clones were picked, expanded in LB medium, and sent for sequencing. After sequence alignment, the plasmid was extracted using the kit to obtain the PRK5-Flag-GFP-SOX10-intron plasmid.
10. The method for detecting mRNA regulatory activity in mammalian oocytes according to claim 1, characterized in that, The process includes: In 12-well plates, when HeLa cells reached a density of 70%-80%, the original culture medium was discarded, and 1 mL of serum-free culture medium was added to each well. 1.5 μL of LIPOFECTAMINE 2000 reagent was diluted in 50 μL of Opti-MEM medium in each well, with 0.5 μg of NMD reporter plasmid and 0.5 μg of HA-mCherry plasmid diluted in 50 μL of Opti-MEM medium used as controls. The mixture was incubated at room temperature for 5 minutes. The diluted plasmid DNA and diluted LIPOFECTAMINE 2000 were mixed and allowed to stand at room temperature for 20 minutes. The resulting mixture was then evenly added to the cells. After incubation at 37°C, 5% CO2, and 100% saturated humidity for 5 hours, 1 mL of fresh DMEM medium containing 10% FBS was added to each well, and the cells were cultured further. Samples were collected 24 hours after transfection for immunofluorescence staining. Remove the cell culture plate, discard the culture medium, wash each well with 1 mL of PBS, add 1 mL of 4% PFA, fix for 30 minutes, and discard the fixative; wash with 1 mL of PBS, add 1 mL of 0.5% Triton X-100, permeabilize for 30 minutes, and discard the permeabilization solution; wash with 1 mL of PBS, add 500 μL of DAPI staining solution, incubate at room temperature for 15 minutes, and discard the staining solution; wash with 1 mL of PBS, add 200 μL of antiquenching agent, and take pictures under a confocal microscope.
Citation Information
Patent Citations
Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
CN101970664A
Staufen 1 (STAU1) - mediated mRNA decay
WO2006039399A2
